Showing 1141-1150 of 21421 results for "".
- Phase III Infant Trial Supports DTcP Immunogenicityhttps://reachmd.com/news/phase-iii-infant-trial-supports-dtcp-immunogenicity/2487947/Key Takeaways In a 3-arm, Phase III comparison, 1,140 healthy infants aged 90 to 119 days were enrolled; DTcP and co-purified DTaP were randomized 1:1, the DTaP-IPV-Hib comparator arm was open-label and nonrandomized, and all vaccines were given at 3, 4, and 5 months.
- Financial Toxicity Common in Insured Brazilian Cancer Patientshttps://reachmd.com/news/financial-toxicity-insured-brazilian-cancer-patients/2487932/Key Takeaways Among 1,343 privately insured patients with breast, prostate, colorectal, or lung cancer treated in a private oncology network in Rio de Janeiro and São Paulo, 23% reported baseline financial burden, 25% reported financial burden at 6 months, and 16% developed Q
- TIVA Versus Inhalational Anesthesia in Sleeve Gastrectomy Trialhttps://reachmd.com/news/tiva-versus-inhalational-anesthesia-in-sleeve-gastrectomy-trial/2487902/Key Takeaways Total intravenous anesthesia was associated with shorter recovery time and lower postoperative nausea and vomiting than inhalational anesthesia. Visual analog scale pain scores were lower at 15 and 30 minutes, with no significant differen
- Resolve Trial Tests Guideline-Informed Physical Therapy for Low Back Painhttps://reachmd.com/news/resolve-trial-tests-guideline-informed-physical-therapy-for-low-back-pain/2487903/Key Takeaways The post-training CPG+PIPT period was associated with fewer opioid prescriptions over 12 months. ODI and DVPRS scores improved slightly more over time during the CPG+PIPT period, but differences were not clinically meaningful at 6 and 12
- Study: Intentional Outdoor Tanning Common Among US Adults, Especially Young Womenhttps://reachmd.com/news/intentional-outdoor-tanning-remains-common-among-us-adults-especially-young-women/2487924/Intentional outdoor tanning remains a common behavior among US adults, particularly younger women, according to a large cross-sectional analysis of nationally representative survey data published online in JAMA Dermatology.<
- Commercial Cardiology Prices Varied Widely Across US Insurershttps://reachmd.com/news/commercial-cardiology-prices-varied-widely-across-us-insurers/2487914/Key Takeaways Using April 2025 Transparency in Coverage data reflecting 2023 contract-year claims, investigators analyzed negotiated prices for 32 common cardiology services across Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna Healthcare, insurers representing 78
- SUBITO Trial Compares Intensified Chemotherapy With Olaparibhttps://reachmd.com/news/subito-trial-compares-intensified-chemotherapy-with-olaparib/2487896/Key Takeaways Overall survival findings were closely aligned between groups, with a reported hazard ratio for death of 1.11. Grade 3-4 cytopenias were common, serious adverse events occurred more often with intensified chemotherapy, and no treatment-re
- Study Identifies Key Trends in GLP-1–Related Plastic Surgery Researchhttps://reachmd.com/news/study-identifies-key-trends-in-glp-1related-plastic-surgery-research/2487864/The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for medical weight management has fueled a surge of interest in their implications for aesthetic and reconstructive plastic surgery, according to a new bibliometric analysis published online ahead of print in Aestheti
- Deucravacitinib in Alopecia Areata: Phase II Trial Findingshttps://reachmd.com/news/deucravacitinib-phase-ii-trial-alopecia-areata/2487863/Key Takeaways Week-24 efficacy endpoints were not met, and secondary endpoints also did not differ from placebo. The phase II multicentre trial used double-blinded, placebo-controlled 1:1:1 randomization to placebo, deucravacitinib 6 mg once daily, or
- Allergan Aesthetics Invests in SkinMedica's Regenerative Science Strategyhttps://reachmd.com/news/allergan-aesthetics-invests-in-skinmedicas-regenerative-science-strategy/2487856/Allergan Aesthetics, an AbbVie company, announced a series of initiatives aimed at expanding SkinMedica's regenerative science platform, including the formation of a Regenerative Science Advisory Board, the expansion of its research and development laboratory, and the launch of physician-based fl